RxDoctor Payments Data

Ryan Planer, MD

Family Medicine · Syracuse, NYNPI 1194106096

Payments from drug & device makers

$3,418in general payments, 2019–2025

Across 179 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$277
  • AbbVie$264
  • Pfizer$258
  • Novo Nordisk$251
  • Boehringer Ingelheim$232
  • AstraZeneca$183
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,418 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$57,024
Medicare patients
238
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$95,059
TrulicityDulaglutide52$64,505
JardianceEmpagliflozin46$60,351
EliquisApixaban46$48,887
MounjaroTirzepatide25$29,786
XareltoRivaroxaban14$22,940
JanuviaSitagliptin Phosphate14$21,226
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$20,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,262
Janumet XrSitagliptin Phos/Metformin Hcl14$18,156
FarxigaDapagliflozin Propanediol11$16,029
MyrbetriqMirabegron17$11,840
Spiriva RespimatTiotropium Bromide16$9,833
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,643
TrintellixVortioxetine Hydrobromide14$7,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$251$95,05973 claims
Lilly USA, LLCTrulicity, Mounjaro$277$94,29177 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Jentadueto Xr$232$75,49673 claims
PfizerEliquis$258$48,88746 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$159$43,84165 claims
MerckJanuvia, Janumet Xr$18$39,38228 claims
AstraZenecaFarxiga, Breztri Aerosphere$183$24,67225 claims
Johnson & JohnsonXarelto$99$22,94014 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$83$7,43314 claims
NovartisEntresto$149$6,84811 claims
AbbVieSynthroid$264$2,70647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →